Gene info: ID 2906

Gene: GRIN2D

GENE ID: 2906

Synonyms: EB11|EIEE46|GluN2D|NMDAR2D|NR2D

Description: glutamate ionotropic receptor NMDA type subunit 2D

Gene type: protein-coding

Location: 19q13.33

dbXrefs: Ensembl:ENSG00000105464 MIM:602717 Vega:OTTHUMG00000183304 UniprotKB:O15399

RefSeq: NG_052829.1

Retrived from: PubMed|SNP Mapped

SNPs: 1 ANCO-SNPs

Phenotype: AD

# Publications: 2

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 4.714e-1 (AD) 5.333e-1 (ND)

ANCO-SNPs

SNP ID	Position	Alleles	Trait	Variation Type
rs34997741	chr19:48432396 (GRCh38.p7)	T>C	alcohol dependence	SNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
ELFN1	0.826
ARX	0.785
CHRNA2	0.76
DLGAP3	0.758
CAMK2N2	0.758
SBK1	0.748
CASKIN1	0.747
SDK1	0.747
DLX2	0.744
BTBD11	0.742

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
MYOT	-0.515
CLEC4E	-0.514
CTNNA3	-0.482
ZFP57	-0.477
FAM107B	-0.47
VRK2	-0.462
SGMS2	-0.45
SEPT10	-0.445
LAYN	-0.438
DTHD1	-0.436

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB00142	Glutamic Acid	Small Molecule	56-86-0	Approved\|Nutraceutical	Target
DB00454	Pethidine	Small Molecule	57-42-1	Approved	Target
DB01173	Orphenadrine	Small Molecule	83-98-7	Approved	Target
DB01520	Tenocyclidine	Small Molecule	21500-98-1	Experimental\|Illicit\|Investigational	Target
DB06151	Acetylcysteine	Small Molecule	616-91-1	Approved\|Investigational	Target
DB00659	Acamprosate	Small Molecule	77337-76-9	Approved\|Investigational	Target
DB06741	Gavestinel	Small Molecule	153436-22-7	Investigational	Target
DB09409	Magnesium acetate tetrahydrate	Small Molecule	16674-78-5	Approved	Target
DB09481	Magnesium carbonate	Small Molecule	546-93-0	Approved\|Investigational	Target
DB13146	Fluciclovine (18F)	Small Molecule	222727-39-1	Approved	Target
DB00289	Atomoxetine	Small Molecule	83015-26-3	Approved	Target
DB00312	Pentobarbital	Small Molecule	76-74-4	Approved\|Investigational	Target
DB00418	Secobarbital	Small Molecule	76-73-3	Approved	Target
DB00996	Gabapentin	Small Molecule	60142-96-3	Approved\|Investigational	Target
DB01174	Phenobarbital	Small Molecule	50-06-6	Approved\|Investigational	Target
DB01708	Prasterone	Small Molecule	53-43-0	Approved\|Investigational\|Nutraceutical	Target
DB04896	Milnacipran	Small Molecule	92623-85-3	Approved\|Investigational	Target
DB06738	Ketobemidone	Small Molecule	469-79-4	Approved\|Investigational	Target

ID	Drug Name	Action	PubMed
C028289	1,5-dihydroxynaphthalene	"1,5-dihydroxynaphthalene metabolite results in increased activity of [GRIN1 protein binds to GRIN2D protein]"	20858708
C491996	(2S,3R)-1-(biphenyl-4-carbonyl)piperazine-2,3-dicarboxylic acid	"(2S,3R)-1-(biphenyl-4-carbonyl)piperazine-2,3-dicarboxylic acid analog binds to and results in decreased activity of [GRIN2D protein binds to GRIN1 protein]"	14718249
C491996	(2S,3R)-1-(biphenyl-4-carbonyl)piperazine-2,3-dicarboxylic acid	"(2S,3R)-1-(biphenyl-4-carbonyl)piperazine-2,3-dicarboxylic acid binds to and results in decreased activity of [GRIN2D protein binds to GRIN1 protein]"	14718249
C050592	3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid	3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid binds to and results in decreased activity of [GRIN2D protein binds to GRIN1 protein]	14718249
C498554	5-(alpha-methyl-4-bromobenzylamino)phosphonomethyl-1,4-dihydroquinoxaline-2,3-dione	"5-(alpha-methyl-4-bromobenzylamino)phosphonomethyl-1,4-dihydroquinoxaline-2,3-dione binds to and results in decreased activity of [GRIN2D protein binds to GRIN1 protein]"	14718249
D000082	Acetaminophen	Acetaminophen affects the expression of GRIN2D mRNA	17562736
D000082	Acetaminophen	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIN2D mRNA	25607892
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased methylation of GRIN2D gene	27153756
D000376	Agmatine	Agmatine results in decreased activity of [GRIN2D protein binds to GRIN1 protein]	15982768
D015074	2-Aminoadipic Acid	2-Aminoadipic Acid binds to and results in decreased activity of [GRIN2D protein binds to GRIN1 protein]	14718249
D015761	4-Aminopyridine	[Bicuculline co-treated with 4-Aminopyridine] results in decreased expression of GRIN2D protein	19911010
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of GRIN2D mRNA	16483693
D000726	Androgen Antagonists	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIN2D mRNA	25607892
D001151	Arsenic	Arsenic affects the methylation of GRIN2D gene	25304211
D001280	Atrazine	Atrazine results in decreased expression of GRIN2D mRNA	25929836
D001640	Bicuculline	[Bicuculline co-treated with 4-Aminopyridine] results in decreased expression of GRIN2D protein	19911010
C006780	bisphenol A	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIN2D mRNA	25607892
C006780	bisphenol A	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIN2D mRNA	25607892
C006780	bisphenol A	bisphenol A results in increased expression of GRIN2D mRNA	18180321\|2518105
C038091	butylparaben	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIN2D mRNA	25607892
C038091	butylparaben	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIN2D mRNA	25607892
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of GRIN2D mRNA	16644059
D000068579	Celecoxib	Celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIN2D mRNA]	21589914
D003042	Cocaine	Cocaine affects the expression of GRIN2D mRNA	20187946
D003042	Cocaine	Cocaine results in increased expression of GRIN2D mRNA	16076954
D003471	Cuprizone	Cuprizone results in decreased expression of GRIN2D mRNA	26577399
D003976	Diazinon	Diazinon results in decreased expression of GRIN2D mRNA	19440498
C000944	dicrotophos	dicrotophos results in increased expression of GRIN2D mRNA	28302478
C038939	enzacamene	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIN2D mRNA	25607892
C038939	enzacamene	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIN2D mRNA	25607892
D000431	Ethanol	Ethanol results in decreased expression of GRIN2D mRNA	20655511
D000431	Ethanol	"N-methyl-N-(6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)aminomethylcarboxylic acid inhibits the reaction [Ethanol results in decreased expression of GRIN2D mRNA]"	20655511
D018690	Excitatory Amino Acid Agonists	Excitatory Amino Acid Agonists results in increased expression of GRIN2D mRNA	28987794
D018690	Excitatory Amino Acid Agonists	Excitatory Amino Acid Agonists results in increased expression of GRIN2D protein	28987794
D005620	Freund's Adjuvant	Freund's Adjuvant results in increased expression of GRIN2D mRNA	20349343
C069837	fullerene C60	fullerene C60 results in decreased expression of GRIN2D mRNA	19167457
C039281	furan	furan results in decreased expression of GRIN2D mRNA	26194646
D019833	Genistein	Genistein results in decreased expression of GRIN2D mRNA	21048042
D006220	Haloperidol	Haloperidol results in decreased expression of GRIN2D mRNA	18923069
D006582	Hexachlorophene	Hexachlorophene results in decreased expression of GRIN2D mRNA	25943520
D007608	Kainic Acid	Celecoxib promotes the reaction [Kainic Acid results in decreased expression of GRIN2D mRNA]	21589914
D007608	Kainic Acid	Kainic Acid results in decreased expression of GRIN2D mRNA	21589914
D007608	Kainic Acid	PTGS2 affects the reaction [Kainic Acid results in decreased expression of GRIN2D mRNA]	21589914
C008261	lead acetate	lead acetate results in decreased expression of GRIN2D mRNA	24260418
C008261	lead acetate	lead acetate results in increased expression of GRIN2D mRNA	24260418
C045463	leflunomide	leflunomide results in increased expression of GRIN2D mRNA	28988120
D008694	Methamphetamine	Methamphetamine results in decreased expression of GRIN2D mRNA	21886566
D015655	1-Methyl-4-phenylpyridinium	1-Methyl-4-phenylpyridinium results in increased expression of GRIN2D mRNA	24810058
D009284	Naphthols	Naphthols metabolite results in decreased activity of [GRIN1 protein binds to GRIN2D protein]	20858708
C028007	nickel monoxide	nickel monoxide results in decreased expression of GRIN2D mRNA	19167457
C520612	N-methyl-N-(6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)aminomethylcarboxylic acid	"N-methyl-N-(6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)aminomethylcarboxylic acid inhibits the reaction [Ethanol results in decreased expression of GRIN2D mRNA]"	20655511
C118580	octylmethoxycinnamate	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of GRIN2D mRNA	25607892
C118580	octylmethoxycinnamate	[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of GRIN2D mRNA	25607892
D010069	Oxadiazoles	Oxadiazoles metabolite results in increased activity of [GRIN1 protein binds to GRIN2D protein]	20858708
D015232	Dinoprostone	GRIN2D results in increased susceptibility to Dinoprostone	9113374
D010616	Phenanthrenes	GRIN2D protein affects the susceptibility to Phenanthrenes	19911010
D010616	Phenanthrenes	Phenanthrenes binds to and results in decreased activity of GRIN2D protein	19911010
D010616	Phenanthrenes	Phenanthrenes binds to and results in decreased activity of [GRIN2D protein binds to GRIN1 protein]	14718249
D010616	Phenanthrenes	Phenanthrenes inhibits the reaction [PLAT protein results in increased activity of GRIN2D protein]	19911010
D010616	Phenanthrenes	Phenanthrenes metabolite binds to and results in decreased activity of GRIN2D protein	19684252
D010616	Phenanthrenes	Phenanthrenes metabolite results in decreased activity of [GRIN1 protein binds to GRIN2D protein]	20858708
D010616	Phenanthrenes	Phenanthrenes metabolite results in increased activity of [GRIN1 protein binds to GRIN2D protein]	20858708
D010879	Piperazines	Piperazines metabolite binds to and results in decreased activity of GRIN2D protein	19684252
D010936	Plant Extracts	Plant Extracts results in decreased expression of GRIN2D mRNA	23557933
D011189	Potassium Chloride	Potassium Chloride results in decreased expression of GRIN2D protein	19911010
C065286	SDZ EAA 494	SDZ EAA 494 binds to and results in decreased activity of [GRIN2D protein binds to GRIN1 protein]	14718249
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of GRIN2D mRNA	27913140
D014635	Valproic Acid	Valproic Acid results in increased methylation of GRIN2D gene	29154799
D001335	Vehicle Emissions	Vehicle Emissions results in increased methylation of GRIN2D gene	25560391

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0004970	ionotropic glutamate receptor activity	-	IDA	27616483
GO:0004972	NMDA glutamate receptor activity	-	IBA	21873635
GO:0004972	NMDA glutamate receptor activity	-	IDA	26919761
GO:0004972	NMDA glutamate receptor activity	-	ISS	-
GO:0004972	NMDA glutamate receptor activity	-	TAS	17526495
GO:0005088	Ras guanyl-nucleotide exchange factor activity	-	TAS	-
GO:0005234	extracellularly glutamate-gated ion channel activity	-	IEA	-
GO:0005515	protein binding	-	IPI	11937501
GO:0022849	glutamate-gated calcium ion channel activity	-	IDA	26875626

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000165	MAPK cascade	-	TAS	-
GO:0001964	startle response	-	IEA	-
GO:0007420	brain development	-	NAS	17526495
GO:0008344	adult locomotory behavior	-	IEA	-
GO:0019722	calcium-mediated signaling	-	IEA	-
GO:0035235	ionotropic glutamate receptor signaling pathway	-	IEA	-
GO:0048167	regulation of synaptic plasticity	-	NAS	17526495
GO:0051930	regulation of sensory perception of pain	-	IEA	-
GO:0060079	excitatory postsynaptic potential	-	IBA	21873635
GO:0060079	excitatory postsynaptic potential	-	IEA	-
GO:0060291	long-term synaptic potentiation	-	IBA	21873635
GO:0097553	calcium ion transmembrane import into cytosol	-	IDA	26875626
GO:0098976	excitatory chemical synaptic transmission	-	NAS	17526495

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005622	intracellular	-	IEA	-
GO:0005886	plasma membrane	-	IBA	21873635
GO:0005886	plasma membrane	-	TAS	-
GO:0005887	integral component of plasma membrane	-	IDA	26875626 26919761
GO:0017146	NMDA selective glutamate receptor complex	-	IBA	21873635
GO:0017146	NMDA selective glutamate receptor complex	-	IDA	26875626 26919761
GO:0017146	NMDA selective glutamate receptor complex	-	TAS	17526495
GO:0030054	cell junction	-	IEA	-
GO:0045211	postsynaptic membrane	-	IEA	-
GO:0098839	postsynaptic density membrane	-	IBA	21873635

KEGG ID	KEGG Term
hsa04020	Calcium signaling pathway
hsa04080	Neuroactive ligand-receptor interaction
hsa04720	Long-term potentiation
hsa05010	Alzheimer's disease
hsa05014	Amyotrophic lateral sclerosis (ALS)

Reactome ID	Reactome Term	Evidence
R-HSA-112314	Neurotransmitter receptors and postsynaptic signal transmission	TAS
R-HSA-112315	Transmission across Chemical Synapses	TAS
R-HSA-112316	Neuronal System	TAS
R-HSA-112316	Neuronal System	IEA
R-HSA-162582	Signal Transduction	TAS
R-HSA-438064	Post NMDA receptor activation events	TAS
R-HSA-438066	Unblocking of NMDA receptor, glutamate binding and activation	TAS
R-HSA-442729	CREB phosphorylation through the activation of CaMKII	TAS
R-HSA-442742	CREB phosphorylation through the activation of Ras	TAS
R-HSA-442755	Activation of NMDA receptor and postsynaptic events	TAS
R-HSA-442982	Ras activation upon Ca2+ influx through NMDA receptor	TAS
R-HSA-5673001	RAF/MAP kinase cascade	TAS
R-HSA-5683057	MAPK family signaling cascades	TAS
R-HSA-5684996	MAPK1/MAPK3 signaling	TAS
R-HSA-6794361	Neurexins and neuroligins	IEA
R-HSA-6794362	Protein-protein interactions at synapses	TAS
R-HSA-6794362	Protein-protein interactions at synapses	IEA
R-HSA-8849932	Synaptic adhesion-like molecules	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
25262781	Expression of glutamatergic genes in healthy humans across 16 brain regions; altered expression in the hippocampus after chronic exposure to alcohol or cocaine. (2014 Nov)	Enoch MA	Genes Brain Behav
18444252	Neurotransmission and bipolar disorder: a systematic family-based association study. (2008 Oct 5)	Shi J	Am J Med Genet B Neuropsychiatr Genet